Cargando…

Clinicoradiological outcomes after radical radiotherapy for lung cancer in patients with interstitial lung disease

OBJECTIVE: Interstitial lung disease (ILD) is relatively common in patients with lung cancer with an incidence of 7.5%. Historically pre-existing ILD was a contraindication to radical radiotherapy owing to increased radiation pneumonitis rates, worsened fibrosis and poorer survival compared with non...

Descripción completa

Detalles Bibliográficos
Autores principales: Walls, Gerard M, McMahon, Michael, Moore, Natasha, Nicol, Patrick, Bradley, Gemma, Whitten, Glenn, Young, Linda, O'Hare, Jolyne M, Lindsay, John, Connolly, Ryan, Linden, Dermot, Ball, Peter A, Hanna, Gerard G, McAleese, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The British Institute of Radiology. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10301718/
https://www.ncbi.nlm.nih.gov/pubmed/37389005
http://dx.doi.org/10.1259/bjro.20220049
Descripción
Sumario:OBJECTIVE: Interstitial lung disease (ILD) is relatively common in patients with lung cancer with an incidence of 7.5%. Historically pre-existing ILD was a contraindication to radical radiotherapy owing to increased radiation pneumonitis rates, worsened fibrosis and poorer survival compared with non-ILD cohorts. Herein, the clinical and radiological toxicity outcomes of a contemporaneous cohort are described. METHODS: Patients with ILD treated with radical radiotherapy for lung cancer at a regional cancer centre were collected prospectively. Radiotherapy planning, tumour characteristics, and pre- and post-treatment functional and radiological parameters were recorded. Cross-sectional images were independently assessed by two Consultant Thoracic Radiologists. RESULTS: Twenty-seven patients with co-existing ILD received radical radiotherapy from February 2009 to April 2019, with predominance of usual interstitial pneumonia subtype (52%). According to ILD-GAP scores, most patients were Stage I. After radiotherapy, localised (41%) or extensive (41%) progressive interstitial changes were noted for most patients yet dyspnoea scores (n = 15 available) and spirometry (n = 10 available) were stable. One-third of patients with ILD went on to receive long-term oxygen therapy, which was significantly more than the non-ILD cohort. Median survival trended towards being worse compared with non-ILD cases (17.8 vs 24.0 months, p = 0.834). CONCLUSION: Radiological progression of ILD and reduced survival were observed post-radiotherapy in this small cohort receiving lung cancer radiotherapy, although a matched functional decline was frequently absent. Although there is an excess of early deaths, long-term disease control is achievable. ADVANCES IN KNOWLEDGE: For selected patients with ILD, long-term lung cancer control without severely impacting respiratory function may be possible with radical radiotherapy, albeit with a slightly higher risk of death.